A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Wongboonma, Wanwisa ^a   Thongnoppakhun, Wanna ^a   Auewarakul, Chirayu U ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ISOLEUCINE; PROTEIN TYROSINE KINASE INHIBITOR; THREONINE;

ALLELE; ALLELE SPECIFIC POLYMERASE CHAIN REACTION; AMINO ACID SUBSTITUTION; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DILUTION; DIRECT SEQUENCING; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; MUTANT; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; DRUG RESISTANCE; GENETICS; METHODOLOGY; MUTATION;

ALLELES; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; POLYMERASE CHAIN REACTION;

EID: 79551688229     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-7     Document Type: Article

References (36)

1. The biology of chronic myelogenous leukemia: implications for imatinib therapy. RH Alvarez H Kantarjian JE Cortes, Semin Hematol 2007 44 4 14 10.1053/j.seminhematol.2006.12.007 17292736
2. The BCR/ABL hybrid gene. J Groffen N Heisterkamp, Baillieres Clin Haematol 1987 1 983 999 10.1016/S0950-3536(87)80035-5 3332859
3. Animal models of chronic myelogenous leukemia. RL Ilaria Jr, Hematol Oncol (Pubitemid 38969130)
4. Translation of the Philadelphia chromosome into therapy for CML. BJ Druker, Blood 2008 112 4808 4817 10.1182/blood-2008-07-077958 19064740
5. Perspectives on the development of imatinib and the future of cancer research. BJ Druker, Nat Med 2009 15 1149 1152 10.1038/nm1009-1149 19812576
6. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. T O'Hare CA Eide MW Deininger, Blood 2007 110 2242 2249 17496200 (Pubitemid 47523141)
7. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. S Cang D Liu, J Hematol Oncol 2008 1 15 10.1186/1756-8722-1-15 18828913
8. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. T Ernst P Erben MC Muller P Paschka T Schenk J Hoffmann S Kreil P La Rosee R Hehlmann A Hochhaus, Haematologica 2008 93 186 192 10.3324/haematol.11993 18223278 (Pubitemid 351397706)
9. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. FE Nicolini MJ Mauro G Martinelli DW Kim S Soverini MC Muller A Hochhaus J Cortes C Chuah IH Dufva, et al. Blood 2009 114 5271 5278 10.1182/blood-2009-04-219410 19843886
10. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? S Branford JV Melo TP Hughes, Blood 2009 114 5426 5435 10.1182/blood-2009-08-215939 19880502
11. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. N von Bubnoff F Schneller C Peschel J Duyster, Lancet 2002 359 487 491 10.1016/S0140-6736(02)07679-1 11853795 (Pubitemid 34164296)
12. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. SH Kim D Kim DW Kim HG Goh SE Jang J Lee WS Kim IY Kweon SH Park, Hematol Oncol 2009 27 190 197 10.1002/hon.894 19274615
13. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. E Jabbour H Kantarjian D Jones M Talpaz N Bekele S O'Brien X Zhou R Luthra G Garcia-Manero F Giles, et al. Leukemia 2006 20 1767 1773 10.1038/sj.leu.2404318 16855631 (Pubitemid 44574988)
14. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Y Qin S Chen B Jiang Q Jiang H Jiang J Li L Li Y Lai Y Liu X Huang, Ann Hematol 2011 90 47 52 10.1007/s00277-010-1039-5 20697894
15. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. J Cortes E Jabbour H Kantarjian CC Yin J Shan S O'Brien G Garcia-Manero F Giles M Breeden N Reeves, et al. Blood 2007 110 4005 4011 10.1182/blood-2007-03-080838 17785585 (Pubitemid 350248456)
16. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. ME Gorre M Mohammed K Ellwood N Hsu R Paquette PN Rao CL Sawyers, Science 2001 293 876 880 10.1126/science.1062538 11423618 (Pubitemid 32743979)
17. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. T Hughes G Saglio S Branford S Soverini DW Kim MC Muller G Martinelli J Cortes L Beppu E Gottardi, et al. J Clin Oncol 2009 27 4204 4210 10.1200/JCO.2009.21.8230 19652056
18. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. NP Shah JM Nicoll B Nagar ME Gorre RL Paquette J Kuriyan CL Sawyers, Cancer Cell 2002 2 117 125 10.1016/S1535-6108(02)00096-X 12204532 (Pubitemid 41039112)
19. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. AS Corbin P La Rosee EP Stoffregen BJ Druker MW Deininger, Blood 2003 101 4611 4614 10.1182/blood-2002-12-3659 12576318 (Pubitemid 36857835)
20. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. C Roche-Lestienne V Soenen-Cornu N Grardel-Duflos JL Lai N Philippe T Facon P Fenaux C Preudhomme, Blood 2002 100 1014 1018 10.1182/blood.V100.3.1014 12130516 (Pubitemid 34832631)
21. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. HA Bradeen CA Eide T O'Hare KJ Johnson SG Willis FY Lee BJ Druker MW Deininger, Blood 2006 108 2332 2338 10.1182/blood-2006-02- 004580 16772610 (Pubitemid 44497517)
22. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? E Jabbour H Kantarjian J Cortes, Semin Hematol 47 344 353 10.1053/j.seminhematol.2010.06.002 20875551
23. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. G Wei S Rafiyath D Liu, J Hematol Oncol 3 47 10.1186/1756-8722-3-47 21108851
24. Response definitions and European Leukemianet Management recommendations. M Baccarani F Castagnetti G Gugliotta F Palandri S Soverini, Best Pract Res Clin Haematol 2009 22 331 341 10.1016/j.beha.2009.10.001 19959084
25. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. D Jones S Kamel-Reid D Bahler H Dong K Elenitoba-Johnson R Press N Quigley P Rothberg D Sabath D Viswanatha, et al. J Mol Diagn 2009 11 4 11 10.2353/jmoldx.2009.080095 19095773
26. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. HY Kang JY Hwang SH Kim HG Goh M Kim DW Kim, Haematologica 2006 91 659 662 16627254 (Pubitemid 43799464)
27. Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants. CU Auewarakul S Huang M Yimyam S Boonmoh, Acta Haematol 2006 116 114 119 10.1159/000093641 16914906 (Pubitemid 44252767)
28. Denaturing High-Performance Liquid Chromatography (DHPLC) for Nucleic Acid Analysis. JM Walker R Rapley KH Leung SP Yip, Molecular Biomethods Handbook Humana Press 2008 89 106
29. Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors. G Manrique Arechavaleta V Scholl V Perez R Bittencourt A Moellmann R Hassan HN Seuanez J Dobbin L Martinez IZ Renault R Uriarte, Clin Exp Med 11 55 59 10.1007/s10238-010-0101-x 20512393
30. Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. MW Deininger L McGreevey S Willis TM Bainbridge BJ Druker MC Heinrich, Leukemia 2004 18 864 871 10.1038/sj.leu.2403307 14973502 (Pubitemid 38500206)
31. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. S Soverini G Martinelli M Amabile A Poerio M Bianchini G Rosti F Pane G Saglio M Baccarani, Clin Chem 2004 50 1205 1213 10.1373/clinchem.2004.031112 15107311 (Pubitemid 38824229)
32. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. T Ernst FX Gruber O Pelz-Ackermann J Maier M Pfirrmann MC Muller I Mikkola K Porkka D Niederwieser A Hochhaus T Lange, Haematologica 2009 94 1227 1235 10.3324/haematol.2009.006981 19608684
33. Double-gradient-denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients. N Sorel F Chazelas A Brizard JC Chomel, Clin Chem 2005 51 1263 1266 10.1373/clinchem.2004.047274 15976107 (Pubitemid 43079409)
34. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. SG Willis T Lange S Demehri S Otto L Crossman D Niederwieser EP Stoffregen S McWeeney I Kovacs B Park, et al. Blood 2005 106 2128 2137 10.1182/blood-2005-03-1036 15914554 (Pubitemid 41291730)
35. High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations. A Vivante N Amariglio M Koren-Michowitz O Ashur-Fabian A Nagler G Rechavi Y Cohen, Leukemia 2007 21 1318 1321 10.1038/sj.leu.2404635 17330094 (Pubitemid 46831827)
36. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. M Baccarani J Cortes F Pane D Niederwieser G Saglio J Apperley F Cervantes M Deininger A Gratwohl F Guilhot, et al. J Clin Oncol 2009 27 6041 6051 10.1200/JCO.2009.25.0779 19884523